NASH Alliance
  • Home
  • About
    • What is NASH?
    • About NASH Alliance
  • Resources
    • NASH Prevention
    • News
    • Publications
    • Additional Information
  • Events
  • Contact
Select Page
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

by ltsiwpadmin | Dec 19, 2018 | Policy & Public Affairs

Non-alcoholic fatty liver disease and nonalcoholic steatohepatitis can lead to advanced liver disease. Both conditions are becoming increasingly prevalent as the epidemics of obesity and diabetes continue to increase. A mathematical model was built to understand how...
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Liver Biopsy in Type 2 Diabetes: Implications for NASH

by ltsiwpadmin | Jun 1, 2017 | Policy & Public Affairs, Publications

Abstract Recent studies report a prevalence of non-alcoholic fatty liver disease (NAFLD) of between 70% and 80% in patients with metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM). Nevertheless, it is not possible to differentiate between simple steatosis and...
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Liver Safety of Statins in Prediabetes or T2DM and NASH

by ltsiwpadmin | Jun 1, 2017 | Policy & Public Affairs, Publications

Abstract CONTEXT Patients with nonalcoholic fatty liver disease have a high cardiovascular risk, but statins are rarely prescribed because of fear of hepatotoxicity. OBJECTIVE To prospectively assess the long-term safety of statins in patients with prediabetes/type 2...
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Liver and Cardiovascular Damage in Patients with NASH

by ltsiwpadmin | May 26, 2017 | Policy & Public Affairs, Publications

Abstract BACKGROUND & AIMS Lean nonalcoholic fatty liver disease (NAFLD) is defined as NAFLD that develops in patients with a body mass index (BMI) less than 25 kg/m2. We investigated the differences between lean NAFLD and NAFLD in overweight and obese persons,...

Recent Posts

  • Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry
  • About Danielle P. Turnipseed, J.D., M.H.S.A., M.P.P.
  • About Billy Wynne, J.D.
  • About Barret Thornhill, J.D.
  • Fatty liver disease strikes Latino children like a ‘silent tsunami’

Recent Comments

    Archives

    • October 2019
    • September 2019
    • July 2019
    • June 2019
    • April 2019
    • December 2018
    • October 2018
    • July 2017
    • June 2017
    • May 2017

    Categories

    • Diagnostics & Therapeutic Advancements
    • News
    • Overview & Epidemiology
    • Policy & Public Affairs
    • Prevention & Management
    • Publications
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    NASH Alliance

    [email protected]

    Follow us on twitter